Hedge Fund - Sabby Capital

You can access the original SEC filing by clicking here.

You can access the original SEC filing by clicking here.

Sabby Healthcare Master Fund, Ltd | 0 | 10,400,000 | 0 | 10,400,000 | 10,400,000 | 7.36 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 232828509 1.

Sabby Healthcare Master Fund, Ltd | 0 | 702,896 | 0 | 702,896 | 702,896 | 7.61 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 68232V108 1.

Sabby Healthcare Master Fund, Ltd | 0 | 3,250,000 | 0 | 3,250,000 | 3,250,000 | 9.70 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 42237K 102 1.

Sabby Healthcare Master Fund, Ltd | 0 | 461,536 | 0 | 461,536 | 461,536 | 3.43 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 247078108 1.

Sabby Healthcare Master Fund, Ltd | 0 | 3,044,391 | 0 | 3,044,391 | 3,044,391 | 6.21 12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO CUSIP No. 58471G201 1.

Sabby Capital actually dumped 68% of its Histogenics Corp (NASDAQ:HSGX) holdings, which is a medicine company, during the third quarter probably when the shares were trading above $3 per share.

Hal Mintz's Sabby Capital recently filed a Form 13G with the SEC, in which it reported the acquisition of 2.48 million common shares of Sophiris Bio Inc.